Telomir Pharmaceuticals, Inc. TELO 深 沪
已收盘 02-06 16:00:00 美东时间
1.15
+0.030
+2.68%
华盛通- 最 高1.19
- 今 开1.11
- 成交量 12.01万股
- 最 低 1.11
- 昨 收 1.12
- 总市值 3953.81万
- 52周最高 5.40
- 市盈率 静 --
- 换手率 0.35%
- 52周最低 1.07
- 委 比 72.00%
- 总股本 3438.10万
- 历史最高 20.72
- 量 比 0.51
- 振 幅 7.14%
- 历史最低 1.07
- 每 手 1
- 风险率 1.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Telomir Pharmaceuticals Announces New Data Supporting Telomir-Zn's Mechanism In Cancer And Aging, Plans Submission For Investigational New Drug Application In Q1 2026
Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity-without relying on cytotoxic mechanisms.
02-05 21:09
Telomir Highlights Positive Preclinical Results for Telomir-1 in TNBC
Telomir Pharmaceuticals, Inc. ( ($TELO) ) just unveiled an update. Telomir Phar...
01-05 21:39
Telomir Pharmaceuticals Results From Trial In Zebrafish Tumor Xenograft Animal Models Of Triple-Negative Breast Cancer Shows Reductions In Primary Tumor Growth, Spread Of Cancer Cells
Telomir Pharmaceuticals (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of diseases, today announced
01-05 21:07
Telomir Pharma Announces Results From Comprehensive Series Of IND-Enabling GLP Toxicology And Safety Pharmacology Studies For Telomir-1
No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration.MIAMI, FL / ACCESS Newswire / December 18, 2025 / Telomir Pharmaceuticals,
2025-12-18 20:32
Telomir Pharmaceuticals Announces Telomir-1 Shown To Kill Aggressive Human Leukemia Cells
Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells The findings expand Telomir-1's oncology profile into cancers of the blood, adding to previously reported activity in triple-negative
2025-11-21 05:05
Telomir Pharmaceuticals Q3 EPS $(0.03) Beats $(0.07) Estimate
Telomir Pharmaceuticals (NASDAQ:TELO) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.07) by 57.14 percent. This is a 85 percent increase over losses of $(0.20) per share
2025-11-11 07:00
Telomir Pharmaceuticals Unveils Promising Preclinical Cancer Data
The latest announcement is out from Telomir Pharmaceuticals, Inc. ( ($TELO) ). ...
2025-10-23 04:40
Telomir Pharmaceuticals executes LOI for worldwide rights to Telomir-1
Telomir Pharmaceuticals (NASDAQ:TELO) said on Tuesday that it has executed a binding Letter of Intent to acquire TELI Pharmaceuticals, securing worldwide rights to its lead investigational therapy, T...
2025-10-21 20:10
Telomir Pharmaceuticals to Acquire TELI Pharmaceuticals
The latest update is out from Telomir Pharmaceuticals, Inc. ( ($TELO) ). On Oct...
2025-10-21 06:26
Telomir-1 Demonstrates Anti-Tumor Activity In Pancreatic Cancer Models, Reinforcing Epigenetic And Metabolic Impact Across Multiple Cancers
Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighting Telomir-1's consistent impact on cancer cell survival pathways.MIAMI, FLORIDA / ACCESS
2025-10-14 20:10
